Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis

NCT04710524 is registered in ClinicalTrials.gov with Future Medicine as lead sponsor.

NCT NCT04710524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04710524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of FM101 in Adults With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
Lead sponsor
Future Medicine
Phase
Phase 2
Overall status
Unknown status
Start date
June 10, 2021
Completion date
August 31, 2023
Enrollment
60 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic fatty liver disease, nonalcoholic steatohepatitis